Skip to main content
. 2020 Feb 5;9(7):2309–2316. doi: 10.1002/cam4.2806

Table 4.

Main results of PEMBREIZH, KEYNOTE‐024 and KEYNOTE‐042

Parameter PEMBREIZH KEYNOTE‐0244, 20

KEYNOTE‐042

(TPS ≥50% subgroup)16

PFS 10,1 mo 95% CI [8,8 to NA] 10.3 mo 95% CI [6,7 to NA] 7,1 mo 95% CI [5,9 to 9,0]
OS 15,2 mo 95% CI [13,9 to NA] 30,0 mo 95% CI [18,3 to NA] 20,0 mo 95% CI [15,4 to 24,9]
ORR 53,7% 44,8% 39%
IrAEs * 8% 9,7% 8%

Abbreviations: IrAEs: immune‐related adverse events; ORR: Objective response rate; OS: Overall survival; PFS: Progression‐free survival